Use of Oral Droxidopa to Improve Arterial Pressure and Reduce Vasoactive Drug Requirements During Persistent Vasoplegic Syndrome After Cardiac Transplantation. J Cardiothorac Vasc Anesth 2016 Dec;30(6):1624-1626
Date
05/11/2016Pubmed ID
27161180DOI
10.1053/j.jvca.2015.12.013Scopus ID
2-s2.0-84965042758 (requires institutional sign-in at Scopus site) 5 CitationsAuthor List
Zundel MT, Boettcher BT, Feih JT, Gaglianello N, Pagel PSAuthors
Brent Boettcher DO Associate Professor in the Anesthesiology department at Medical College of WisconsinNunzio A. Gaglianello MD Associate Professor in the Medicine department at Medical College of Wisconsin
Michael Tracy Zundel MD Associate Professor in the Anesthesiology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Administration, OralAntiparkinson Agents
Arterial Pressure
Droxidopa
Fatal Outcome
Female
Heart Transplantation
Humans
Middle Aged
Multiple Organ Failure
Postoperative Complications
Syndrome
Vasoplegia